Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy

By sjmartinez • September 19, 2024

Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy. Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. PMID: 39291206; PMCID: PMC11403052.

Tags: Clinical Trial, felzartamab, Harbor UCLA, MOR202, Nephrology, phase 2, phospholipase A2 receptor, primary membranous nephropathy, Publications

Impact of Nonalcoholic Hepatic Steatosis on the Warranty Period of a Coronary Artery Calcium Score of 0: Results From the Multi-Ethnic Study of Atherosclerosis

Ichikawa K, Lim J, McClelland RL, Susarla S, Krishnan S, Benzing T, Kianoush S, Aldana-Bitar J, Manubolu VS, Budoff MJ. Impact of Nonalcoholic Hepatic Steatosis[...]

Brief Report: Low-Dose Methotrexate Does Not Affect Measures of HIV-1 Persistence in Individuals With Chronically Treated HIV-1 Infection

Cyktor JC, Yeh E, Ribaudo H, Hoeth D, Naqvi A, Bell T, Ridker PM, Fichtenbaum C, Daar ES, Havlir D, Tawakol A, Lederman MM, Stein[...]

Sulfated glycosaminoglycans are host epithelial cell targets of the Candida albicans toxin candidalysin

Lin J, Miao J, Schaefer KG, Russell CM, Pyron RJ, Zhang F, Phan QT, Solis NV, Liu H, Tashiro M, Dordick JS, Linhardt RJ, Yeaman[...]